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toms. METHODS: Randomized controlled trials (RCT) of adali-
mumab, etanercept and inﬂiximab involving patients with
PsA were searched in MEDLINE by Cochrane Highly Sensitive
Search Strategy. The quality of selected studies was measured
using the Jadad-score. Two clinical outcomes were analyzed:
the rate of patients achieving at least 20% improvement by the
American College of Rheumatology criteria (ACR20) and the
Psoriatic Arthritis Response Criteria (PsARC). Review Manager
4.2 software was applied for the analysis, using the number
needed to treat (NNT) and relative risk (RR) as statistical
variables. Due to lack of face-to-face evidence on biologicals, in-
direct comparison was conducted applying Butcher’s method.
RESULTS: Six RCTs were identiﬁed involving altogether 982
patients on the active treatment arms: adalimumab (n = 413),
etanercept (n = 265) and inﬂiximab (n = 304). All trials were
placebo controlled, the primary follow-up time was 12–16 weeks
and the primary outcome was ACR20. The NNTs (95% conﬁ-
dence intervals) for adalimumab, etanercept and inﬂiximab were
2.6 (2.1–3.2), 2.1 (1.7–2.7) and 2.0 (1.7–2.4) patients to achieve
ACR20 outcome and 2.9 (2.3–4.0), 2.2 (1.8–2.8) and 2.0
(1.6–2.4) to fulﬁll PsARC outcome, respectively. Indirect pair-
wise comparisons of TNF-alpha inhibitors yielded the RR of
0.87 (0.50–1.51) for adalimumab vs. etanercept, of 1.37 (0.72–
2.61) for inﬂiximab vs. etanercept and of 1.57 (0.87–2.86) for
inﬂiximab vs. adalimumab. CONCLUSION: Adalimumab, etan-
ercept and inﬂiximab are effective for the treatment of PsA. Both
the NNTs and the responsiveness of the three drugs at PsARC
and ACR20 outcomes are similar. Indirect comparison did not
reveal signiﬁcant difference in the efﬁcacy among the TNF-alpha
inhibitors in PsA.
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OBJECTIVE: To compare the efﬁcacy of etoricoxib, lumira-
coxib, celecoxib, non-selective (ns) NSAIDs and acetaminophen
in the treatment of osteoarthritis. METHODS: RCTs investigat-
ing the effects of acetaminophen 4000 mg, diclofenac 150 mg,
naproxen 1000 mg, ibuprofen 2400 mg, celecoxib 100–400 mg,
lumiracoxib 100–400 mg, and etoricoxib 60 mg with a treat-
ment duration of at least two weeks were identiﬁed with a
systematic literature search. Endpoints of interest were pain,
physical function and patient global assessment of disease status
(PGADS). Pain and physical function reported on VAS or
LIKERT scales were translated into effect sizes (ES). PGADS was
reported on a 0–100 mm VAS scale. An ES 0.2–0.5 was deﬁned
as a “small” treatment effect, whereas ES of 0.5–0.8 and >0.8were
deﬁned as “moderate” and “large”, respectively. Outcomes of all
trials were analyzed simultaneously with a Bayesian mixed treat-
ment comparison. A negative estimate indicates favourable out-
comes. RESULTS: There is an 84% probability that etoricoxib
60 mg shows the greatest improvement in pain of all interventions
compared, followed by diclofenac 150 mg (7% probability) and
ibuprofen 2400 mg (4%). Etoricoxib 60 mg showed an ES of
-0.62 (95%Credible Interval -0.78; -0.45) relative to placebo, an
ES of -0.12 (-0.33; 0.07) relative to diclofenac 150 mg, and an ES
of -0.21 (-0.50; 0.07) relative to ibuprofen. Regarding physical
functioning, there is an 85% probability that etoricoxib 60 mg
showed the greatest improvement, followed by diclofenac 150 mg
(8% probability) and ibuprofen 2400 mg (4%). ESs of etoricoxib
60 mg relative to diclofenac 150 mg and ibuprofen 2400 mgwere
-0.12 (-0.34; 0.08), and -0.23 (-0.53; 0.06) respectively. The
greatest improvements regarding PGADS were expected with
diclofenac (29% probability) followed by etoricoxib (25%).
CONCLUSION: The current study estimated the efﬁcacy of
acetaminophen, nsNSAIDs, and COX-2 selective NSAIDs in OA
and demonstrated that etoricoxib 60 mg is likely to result in the
greatest improvements in pain and physical function.
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OBJECTIVE: The aim of our study was to examine the relation-
ship between volume (annual number of patients) and outcome
(30 days mortality) in patients with femoral neck fracture.
METHODS: Data derived from the nationwide dataset of the
National Health Insurance Fund Administration. Patients aged
over 60 years with femoral neck fracture admitted to acute care
hospital were included into the study. 30 days mortality follow-
ing the primary surgical treatment was analyzed. We examined
the relationship between volume (annual number of patients) and
outcome (30 days mortality). First quintiles with similar patient
number was applied (method I), than the patient number itself
was the variable (method II). Several other covariates were
included into the analysis: sex, age, co-morbidities, type and
location of fracture, type of surgery (ostheosynthesis, arthro-
plasty), within 30 days complications, hospital type, day of
surgery and surgical delay. The association between covariates
was evaluated with logistic regression analysis (OR: odds ratio,
95% CI: conﬁdence interval, p value). RESULTS: Altogether
3783 patient from 65 different hospitals were included into the
study. The average 30 days mortality was 8.99 %, ranging
between 7.82–10.0 % (method I). Using the volume data itself as
continuous variable (method II), the connection between volume
and outcome could not be proven (ORunivariate = 0.998,
CI: 0.9974–1.0005, p: 0.1779; ORmultivariate = 0.9987, CI:
0.9962–1.0013, p: 0.3378). We did not ﬁnd any relationship
between hospital volume and outcome in patients with femoral
neck fracture. However it is important to highlight the role of
hospital type, where treatment at medical university (medical
school) is associated with signiﬁcantly lower 30 days mortality.
CONCLUSION: We would like to emphasize on the analysis of
our nationwide dataset that initial treatment in high-volume
hospitals was not associated with lower 30 days mortality.
However, type of hospital (teaching status) seems to be more
important predictor of 30 days mortality.
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OBJECTIVE: To understand the impact of the October 2004
withdrawal of rofecoxib on prescription analgesic use for arthri-
tis patients who had been taking this medication. METHODS:
Patients were selected from the MarketScan databases who,
during January-September 2004, had a diagnosis of osteoarthri-
tis on a medical claim and who ﬁlled prescriptions for at least 90
days of therapy with rofecoxib, an alternative COX-2 inhibitor
(celecoxib), or a branded, non-selective, nonsteroidal, anti-
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inﬂammatory drug (NSAID) (meloxicam). For each cohort, use
of prescription analgesics was tracked pre-withdrawal (January-
September 2004) and post-withdrawal (2005–2006). The impact
of the withdrawal on drug utilization by former rofecoxib users
was assessed by comparing changes in their drug consumption
with that of celecoxib or meloxicam users during the same time
period. RESULTS: The study cohorts included: 29,438 rofe-
coxib, 34,937 celecoxib, and 7131 meloxicam users. The groups
were demographically similar, except for a higher proportion of
women in the meloxicam cohort. In 2005, former rofecoxib users
primarily substituted other COX-2 inhibitors (22% celecoxib,
10% valdecoxib) or non-selective NSAIDS (which increased to
48% from 14% pre-withdrawal). There was no substantial
change in use of opioid /other analgesics. The percentage of
former rofecoxib users continuing to receive any prescription
analgesic was 83% (2005) and 77% (2006). By comparison,
overall utilization of celecoxib and meloxicam declined to 87%
and 91% respectively in 2005 and 80% and 84% respectively in
2006. By 2006, 59% of celecoxib users and 53% of meloxicam
users had discontinued these medications. CONCLUSION: By
2006, the proportion of former rofecoxib users who had discon-
tinued prescription analgesics altogether was substantially higher
than among patients who not previously receiving a COX-2
inhibitor. This suggests the potential harm from unsafe drugs
may not be limited to side effects, but also includes the disruption
of care due to withdrawal of effective treatment.
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OBJECTIVE: Abatacept is a new biological DMARD with selec-
tive co-stimulation modulator mechanism of action that was
recently approved in Brazil for the treatment of patients with
moderate to severe RA. We aim to evaluate and describe the
budget impact of the inclusion of abatacept in the National
Program of Exceptional Medications (NPEM) with the tumor
necrosis factor (TNF) antagonists currently in use and included.
METHODS: Using data provided by Brazilian Ministry of
Health, our study estimates the cost associated with the inclusion
of Abatacept for inadequate responders to methotrexate and
TNF antagonists compared with actual scenario (without Abata-
cept). Our model presumes: adequate doses and regimen of
abatacept (10 mg/kg. 0, 2, 4, and each 4 weeks), inﬂiximab
(4.2 mg/kg each dose of inﬂiximab, 0, 2, 6, and each 8 weeks),
etanercept (25 mg each dose/twice a week) and adalimumab
(40 mg each dose, twice a month), and we accept the actual
distribution of TNF antagonists used by NPEM (with adoption
of 20% of increase in the number of the RA patients each
year—NPEM data). According to literature, 30% of the patients
with inadequate response to methotrexate will be eligible to use
abatacept, and we accept this percentage to introduce patients in
the abatacept group. The initial population is 4978 patients
currently in use of TNF antagonists in 2007. RESULTS: In the
ﬁrst year of inclusion there is an increase in costs of R$3,085,711
(US$1,763,263). In the second and third years there are signiﬁ-
cant savings on budgets, R$97,593,971 (US$55,767,983) and
R$129,458,357 (US$73,976,204), respectively. CONCLUSION:
The incorporation of abatacept into the NPEM is cost-saving to
the Brazilian Public Health System, saving R$129,458,357.00
(US$73,976,204) after the third year.
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OBJECTIVE: To conduct a cost-beneﬁt analysis to compare the
hypothetical introduction of a new intervention, internal ﬁxation
(IF), with hemiarthroplasty (HA) for the treatment of displaced
femoral neck fractures in patients greater than 60 years old.
METHODS: We estimated the costs from a third party payer
perspective after one year of two strategies (HA and IF) for the
treatment of femoral neck fractures in patients over the age of 60.
Using a decision board, we elicited patient preferences for the
two operative approaches and calculated the net beneﬁt using the
willingness-to-pay technique. RESULTS: The 1-year projected
cost of one IF was $18,100 and that of one HA was $15,843
(incremental cost of $2,257 for each IF). Of 108 participants, 61
(56.5%) chose IF as the preferred treatment option and were
willing to pay an average of $3.33 per month to have this option
available if needed. In Ontario, the total incremental cost of
performing IF in patients that choose it was $64,714,103, and
the total societal beneﬁt was $289,263,600, yielding a net beneﬁt
of $224,549,497. CONCLUSION: The beneﬁts of IF over HA
outweigh the incremental costs from the perspective of a third
party payer. Therefore, IF should be available to patients that
choose it.
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OBJECTIVE: Total hip arthroplasty (THA) is a common and
successful procedure with nearly 250,000 primary arthroplasties
performed yearly in the United States. This number is estimated
to increase by at least 5% annually over the next decade. The
resulting growth in health care utilization and costs maybe offset
by innovative implant technologies with increased survivorship.
This study quantiﬁes the economic cost savings to payers
from improved survivorship. METHODS: A simulation model
is developed to estimate the long-term cost implications of
improvements in THA survivorship. The model considers costs
associated with all primary hip replacements performed in the
United States over a ten-year horizon. The analysis draws upon
the literature to obtain information on long-term revision rates
for hip replacement surgeries. Inpatient treatment costs associ-
ated with THA and incidence and costs of the major complica-
tions, deep vein thrombosis and infection are included in the
model. RESULTS: Improved implant survivorship in THA is
estimated to save $1.6 billion over a ten-year horizon. The ma-
jority of these savings accrues from lower revision rates ($1.3
billion) with fewer complications accounting for $300 million in
additional savings. Sensitivity analyses reveal that cost savings
varied by survivorship ($1.1 to $2.0 billion) and hospital cost for
revision surgery ($1.3 to $3.1 billion). Other variations by phy-
sician costs, complications costs and discount rates are less pro-
nounced. However, under every scenario, costs savings are in
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